Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by forhandlarenon Mar 23, 2023 1:48pm
171 Views
Post# 35356756

RE:RE:New Financing

RE:RE:New Financing I'm not prepared to call the deal with Abbvie incompetent as I don't know all aspects. The milestones are not public nor the royalty rate or anticipated market share.

That said, I was pretty upset about the upfront - far from my expectations. I think this deal was tailorized for a buyout, meaning that the future revenue stream is more worth than a big upfront now.

But with the R+F (predators) street cred deal in mind I would have acted differently, better upfront to secure a higher share price and better prepared to keep the company floating in the wait for the next revenue opportunity.

Howard seems to only think about the treasure at the end of the rainbow, since he is not an experienced businessman. In addition, he still think that people trust what he says, these days are long gone by now. It`s all about facts and figures after he has burned so many investors.

I remember when a high ranking doctor at each department in our hospital was given budget responsibility - disaster! No awareness that issues must be handled over the course of the financial year - every penny was booked day one...
<< Previous
Bullboard Posts
Next >>